Dose Assessment of Melatonin in Sepsis Trial

NCT ID: NCT02319265

Last Updated: 2017-04-21

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1/PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-04-30
• Study Completion Date: 2019-12-31

Brief Summary

DAMSEL 2 is a pilot Phase II study in patients with sepsis. Stage 1 will assess the pharmacokinetics of melatonin and its major metabolite after a single dose of 50 or 100mg exogenous melatonin in two small groups of patients with sepsis in order to make dosing and dosing interval decisions for Stage 2.

Stage 2 is a double blind randomised controlled trial of melatonin in patients with sepsis at the dose and dosing interval decided after Stage 1. Measurements of melatonin and its major metabolite, and an array of biomarkers of inflammation and oxidative stress will be made, plus transcriptome (mRNA) analysis. This study will inform a planned larger phase II trial.

Detailed Description

Antioxidant therapy targeted at mitochondria has the potential to reduce inflammation, mitochondrial damage and organ dysfunction in sepsis. Melatonin accumulates in mitochondria and both it and its metabolites have potent antioxidant and anti-inflammatory activity, preventing organ dysfunction in a rat model of sepsis. In a recent Phase I dose escalation study (DAMSEL 1) the investigators showed that oral doses of melatonin in healthy subjects were well tolerated with no adverse events and resulted in levels of circulating melatonin and its major metabolite which had beneficial anti-inflammatory and antioxidant actions in ex vivo studiesStage 1 will assess the pharmacokinetics of melatonin and its major metabolite after a single dose of 50 or 100mg exogenous melatonin in two small groups of patients with sepsis in order to make dosing and dosing interval decisions for Stage 2.

Stage 2 is a double blind randomised controlled trial of melatonin in patients with sepsis at the dose and dosing interval decided after Stage 1. Measurements of melatonin and its major metabolite, and an array of biomarkers of inflammation and oxidative stress will be made, plus transcriptome (mRNA) analysis. This study will inform a planned larger phase II trial.

Conditions

Sepsis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Melatonin

Melatonin at a dose of either 50mg (50ml) or 100mg (100ml) to be decided after an initial PK study to be given at intervals to be decided after PK data is available, for 72h. Oral liquid via nasogastric tube.

Group Type: EXPERIMENTAL

Melatonin

Intervention Type: DRUG

Oral liquid

Placebo

Placebo at a dose of either 50ml or 100ml (to be decided after an initial PK study) to be given at intervals to be decided after PK data, is available for 72h. Oral liquid via nasogastric tube.

Group Type: PLACEBO_COMPARATOR

Melatonin

Intervention Type: DRUG

Oral liquid

Interventions

Melatonin

Oral liquid

Intervention Type: DRUG

Other Intervention Names

N-acetyl-5-methoxytryptamine

Eligibility Criteria

Inclusion Criteria

Adult patients (16 years or over) on the ICU at Aberdeen Royal Infirmary with sepsis due to community acquired pneumonia who are within 24h of fulfilling the criteria for sepsis with clinical suspicion of pneumonia and the presence of chest X-ray changes consistent with pneumonia will be recruited. The criteria for sepsis are:

• clinical suspicion or evidence of acute infection
• systemic inflammatory response syndrome, defined by two or more of the following:

1. Core temperature <36 or >38°C;

2. tachycardia: heart rate > 90 beats/min;

3. tachypnoea: respiratory rate > 20 breaths/min or ventilated;

4. leucocyte count >12 x 109/L or <4 x 109/L.

Exclusion Criteria

• <16 years old,
• have a life expectancy <24h,
• have metastatic cancer or immunosuppression,
• are receiving steroids (>20mg/d prednisolone or equivalent, used regularly for >2 weeks prior to ICU admission)
• women of child bearing potential without a negative pregnancy test or a history of surgical sterilization.
• patients receiving fluvoxamine or nifedipine,
• have overt hepatic failure
• unable to tolerate oral medication
• known to be hypersensitive to trial medication and/or excipients

• Minimum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Aberdeen

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Helen Galley

Role: STUDY_DIRECTOR

Univetsity of Aberdeen

Locations

Aberdeen Royal Infirmary

Aberdeen, Scotland, United Kingdom

Countries

United Kingdom

Other Identifiers

3/035/14

Identifier Type: -

Identifier Source: org_study_id